Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jul;11(7):1241-1246.
doi: 10.21037/tlcr-22-520.

Resectable non-small cell lung cancer: an evolving landscape

Jerold Loh  1 , Silvana T Wijaya  1 , Kenneth Sooi  1 , Puey Ling Chia  2 , Ross A Soo  1
Affiliations
Editorial

Resectable non-small cell lung cancer: an evolving landscape

Jerold Loh et al. Transl Lung Cancer Res. 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-520/coif). PLC is on the advisory board of Merck, Bayer, Astrazeneca, Amgen, Pfizer and Roche. RAS is on the advisory board of Amgen, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Janssen, Lily, Merck, Merck Serono, Novartis, Pfizer, Puma, Roche, Taiho, Takeda, Thermo Fisher and Yuhan. He has research grants from Astra-Zeneca and Boehringer Ingelheim. The other authors have no conflicts of interest to declare.

Comment on

  • Transl Lung Cancer Res. 11:1247.

Similar articles

See all similar articles

References

    1. Duan J, Tan F, Bi N, et al. Expert consensus on perioperative treatment for non-small cell lung cancer. Transl Lung Cancer Res 2022;11:1247-67. doi: 10.21037/tlcr-22-527 - DOI - PMC - PubMed
    1. FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations 2020. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro...
    1. Zito Marino F, Ronchi A, Accardo M, et al. Concomitant ALK/KRAS and ALK/EGFR mutations in non small cell lung cancer: different profile of response to target therapies. Transl Cancer Res 2017;6:S457-60. 10.21037/tcr.2017.03.77 - DOI
    1. Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2020;383:1711-23. 10.1056/NEJMoa2027071 - DOI - PubMed
    1. Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 2018;19:139-48. 10.1016/S1470-2045(17)30729-5 - DOI - PubMed

Publication types